Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05907954 · ClinicalTrials.gov registry record · Phase 2
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by IDEAYA Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 18
- Study locations
NCT05907954: Active Phase 2 study of Uveal Melanoma, sponsored by IDEAYA Biosciences.
NCT05907954 is a Phase 2 study of Uveal Melanoma that is active but no longer recruiting, run by IDEAYA Biosciences. The registered enrollment target is 160 participants, above the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (14% higher). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05907954, a Phase 2 study of Uveal Melanoma, is active but no longer recruiting, sponsored by IDEAYA Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 18
- Study locations
Study Summary
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Primary Outcome
Treatment emergent adverse events will be summarized by all AEs, all Grade 3-4-5 AEs, all treatment related AEs, all AEs leading to study drug modifications or discontinuations, all SAEs. Lab results will be summarized by change from baseline values, frequency of newly occurring on-treatment Grade 3 or 4 events; worst on-treatment value compared to baseline.
Conditions Studied
Interventions
- DRUG Darovasertib
Study Locations (18)
Other
- Institute Curie - Paris
- Charité - Universitätsmedizin Berlin - Berlin
- Fondazione IRCCS Istituto Nazionale Tumori - Milan
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Rome
- Leiden University Medical Center - Leiden
California
- Moores Cancer Center - La Jolla
- Stanford Cancer Institute - Palo Alto
Arizona
- HonorHealth Research Institute - Scottsdale
Florida
- University of Miami - Miami
Michigan
- The Cancer and Hematology Centers - Grand Rapids
Minnesota
- Mayo Clinic Rochester - Rochester
New York
- Northwell - Manhasset
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
What the registry record for NCT05907954 still lists
NCT05907954 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 140-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (14% higher).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Darovasertib is the first listed.
NCT05907954 lists 18 locations in 13 states (Other, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT05907954 about?
NCT05907954 is a clinical study titled "(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma". Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
What is the current status of trial NCT05907954?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2023-07-03. Estimated completion is 2030-04-30.
What conditions does trial NCT05907954 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT05907954?
The interventions under investigation include: Darovasertib (DRUG).
Who is sponsoring clinical trial NCT05907954?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05907954 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05907954's enrollment target sits among peer trials
160 6th of 29 higher than 24 of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI